Anticoagulation in atrial fibrillation: What is certain and what is to come

European Heart Journal, Supplement

Volumn 5, Issue H, 2003, Pages

  Villani, Giovanni Quinto ^a   Piepoli, M ^a   Villani, P E ^a   Capucci, A ^a  

^a Ospedale Civile   (Italy)

Author keywords

Anticoagulant therapy; Atrial fibrillation

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; DIPYRIDAMOLE; INDOBUFEN; INDOPROFEN; WARFARIN;

ANTICOAGULANT THERAPY; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CONFERENCE PAPER; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; DRUG SAFETY; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HUMAN; PATIENT COMPLIANCE; PRIORITY JOURNAL; THROMBOEMBOLISM;

EID: 0141960854     PISSN: 1520765X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1520-765X(03)90023-X     Document Type: Conference Paper

References (47)

1. Feinberg WM, Blackshear JL, Laupacis A, et al. Prevalence, age distribution and gender of patients with atrial fibrillation. Analysis and implications. Arch Intern Med 1995;155:469-73.
2. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham study. Stroke 1991;22:983-8.
3. Petersen P, Boysen G, Godtfredsen J, et al. Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK study. Lancet 1989;1:175-9.
4. The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. N Engl J Med 1990;323:1505-11.
5. Stroke Prevention in Atrial Fibrillation Study. Final results. Circulation 1991;84:527-39.
6. Connolly SJ, Laupacis A, Gent M, et al. Canadian Atrial Fibrillation Anticoagulation (CAFA) Study. J Am Coll Cardiol 1991;18:349-55.
7. Ezekowitz MD, Bridgers SL, James KE, et al. Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators. N Engl J Med 1992;327:1406-12.
8. EAFT (European Atrial Fibrillation Trial) Study Group. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. Lancet 1993;342:1255-62.
9. Hart RG, Benavente D, McBride R, et al. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann Intern Med 1999;131:492-501.
10. Petersen P, Boyson G, Godtfredsen J et al. Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK study. Lancet 1989;1:175-9.
11. Gullov AL, Koefoed BG, Petersen P, et al. Fixed minidose warfarin and aspirin alone and in combination vs adjusted-dose warfarin for stroke prevention in atrial fibrillation: Second Copenhagen Atrial Fibrillation, Aspirin, and Anticoagulation Study. Arch Intern Med 1998;158:1513-21.
12. Posada IS, Barriales V. Alternate-day dosing of aspirin in atrial fibrillation. LASAF Pilot Study Group. Am Heart J 1999;138:137-43.
13. Diener HC, Lowenthal A. Antiplatelet therapy to prevent stroke: risk of brain hemorrage and efficacy in atrial fibrillation. J Neurol Sci 1997;153:112.
14. Hellemons BS, Langerberg M, Lodder J, et al. Primary prevention of arterial thromboembolism in patients with nonrheumatic atrial fibrillation in general practice (the PATAF study) [abstract]. Cerebrovasc Dis 1997;7(Suppl 4):11.
15. Benavente O, Hart R, Koudstaal P, et al. Antiplatetet therapy for preventing stroke in patients with nonvalvular atrial fibrillation and no previous history of stroke or transient ischemic attack. In: Warlow C, Van Gijn J, Sandercock P, eds. Stroke module of Cochrane database of systematic reviews. Oxford: The Cochrane Collaboration; 1999:121-8.
16. Hart RG, Pearce LA, Miller VT, et al. Cardioembolic vs. noncardioembolic strokes in atrial fibrillation: frequency and effect of antithrombotic agents in the stroke prevention in atrial fibrillation studies. Cerebrovasc Dis 2000;10:39-43.
17. Laupacis A, Albers G, Dalen J, et al. Antithrombotic therapy in atrial fibrillation. Chest 1998;114(5 Suppl):579S-89S.
18. The European Atrial Fibrillation Trial Study Group. Optimal oral anticoagulant therapy in patients with nonrheumatic atrial fibrillation and recent cerebral ischemia. N Engl J Med 1995;333:5-10.
19. Stroke prevention in Atrial Fibrillation Investigators. Predictors of thromboembolism in atrial fibrillation: I. Clinical features of patients at risk. Ann Intern Med 1992;116:1-5.
20. Stroke Prevention in Atrial Fibrillation Investigators. Predictors of thromboembolism in atrial fibrillation: II. Echocardiographic features of patients at risk. Ann Intern Med 1992;116:6-12.
21. Hart RG, Pearce LA, McBride R, et al. Factors associated with ischemic stroke during aspirin therapy of atrial fibrillation: analysis of 2012 participants in the SPAF I-III clinical trials. The Stroke Prevention in Atrial Fibrillation (SPAF) Investigators. Stroke 1999;30:1223-9.
22. Goldstein LB, Adams R, Becker K, et al. Primary prevention of ischemic stroke: a statement for healthcare professionals from the Stroke Council of the American Heart Association. Circulation 2001;103:163-82.
23. Levy S, Breithardt G, Campbell RW, et al. Atrial fibrillation: current knowledge and recommendations for management. Working Group on Arrhythmias of the European Society of Cardiology. Eur Heart J 1998;19:1294-320.
24. Buckingham TA, Hatala R. Anticoagulants for atrial fibrillation: why is the treatment rate so low? Clin Cardiol 2002;25:447-54.
25. Ibrahim SA, Kwoh CK. Underutilization of oral anticoagulant therapy for stroke prevention in elderly patients with heart failure. Am Heart J 2000;140:219-20.
26. Brass LM, Krumholz HM, Scinto JM, et al. Warfarin use among patients with atrial fibrillation. Stroke 1997;28:2382-9.
27. Bungard TJ, Ackman ML, Ho G, et al. Adequacy of anticoagulation in patients with atrial fibrillation coming to a hospital. Pharmacotherapy 2000;20:1060-5.
28. Levine MN, Raskob G, Landefeld S, et al. Hemorrhagic complications of anticoagulant treatment. Chest 2001;119(1 Suppl):108S-21S.
29. Sebastian JL, Tresch DD. Use of oral anticoagulants in older patients. Drugs Aging 2000;16:409-35.
30. Laupacis A, Albers G, Dale J, et al. Antithrombotic therapy in atrial fibrillation. Chest 1995;108(4 Suppl):352S-9S.
31. Taylor FC, Cohen H, Ebrahim S. Systematic review of long term anticoagulation or antiplatelet treatment in patients with non-rheumatic atrial fibrillation. BMJ 2001;322:321-6.
32. Gage BF, Cardinalli AB, Owens DK. Cost-effectiveness of preference-based antithrombotic therapy for patients nonvalvular atrial fibrillation. Stroke 1998;29:1083-91.
33. Gustafsson C, Asplund K, Britton M et al. Cost effectiveness of primary stroke prevention in atrial fibrillation: a Swedish national perspective. BMJ 1992;305:1457-60.
34. Protheroe J, Fahey T, Montgomery AA, et al. The impact of patients' preferences on the treatment of atrial fibrillation: an observational study of patient based decision analysis. BMJ 2000;320:1380-4.
35. Matchan DB, McCrory DC, Barnett HJ, et al. Medical treatment for stroke prevention. Ann Intern Med 1994;121:41-53.
36. Poller L, Shiach CR, MacCallum PK, et al. Multicentre randomised study of computerised anticoagulant dosage. Lancet 1998;352:1505-9.
37. Fitzmaurice DA, Hobbs FD, Delaney BC, et al. Review of computerised decision support systems for oral anticoagulation management. Br J Haematol 1998;102:907-9.
38. Taylor FC, Gray A, Cohen H, et al. Costs and effectiveness of a nurse specialist anticoagulant service. J Clin Pathol 1997;50:823-8.
39. Watzke HH, Forberg E, Svolba G, et al. A prospective controlled trial comparing weekly self-testing and self-dosing with the standard management of patients on stable oral anticoagulation. Thromb Haemost 2000;83:661-5.
40. Beyth RJ, Quinn L, Landefeld CS. A multicomponent intervention to prevent major bleeding complications in older patients receiving warfarin. A randomized, controlled trial. Ann Intern Med 2000;133:687-95.
41. Man-Son-Hing M, Laupacis A, O'Connor AM, et al. A patient decision aid regarding antithrombotic therapy for stroke prevention in atrial fibrillation: a randomized controlled trial. JAMA 1999;282:737-43.
42. Thomson R, Parkin D, Eccles M, et al. Decision analysis and guidelines for anticoagulant therapy to prevent stroke in patients with atrial fibrillation. Lancet 2000;355:956-62.
43. Morocutti C, Amabile G, Fattapposta F, et al. Indobufen versus warfarin in the secondary prevention of major vascular events in nonrheumatic atrial fibrillation. SIFA (Studio Italiano Fibrillazione Atriale) Investigators. Stroke 1997;28:1015-21.
44. Diener HC, Cunha L, Forbes C, et al. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci 1996;143:1-13.
45. Camm AJ. Atrial fibrillation: is there a role for low-molecular-weight heparin? Clin Cardiol 2001;24(3 Suppl):115-9.
46. Harenberg J, Weuster B, Pfitzer M, et al. Prophylaxis of embolic events in patients with atrial fibrillation using low molecular weight heparin. Semin Thromb Hemost 1993;19 (Suppl 1):116-21.
47. Sievert H, Lesh MD, Trepels T, et al. Percutaneous left atrial appendage transcatheter occlusion to prevent stroke in high-risk patients with atrial fibrillation: early clinical experience. Circulation 2002;105:1887-91.